Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Harald Zeuner"'
Autor:
Günter Fingerle-Rowson, Tina Nielsen, Jeffrey M. Venstrom, Christian Klein, Andres Cardona, Christopher R. Bolen, Nathalie Spielewoy, Deniz Sahin, Andrea Knapp, Harald Zeuner, Valentin Goede, Alexandra Bazeos, Umberto Vitolo, Laurie H. Sehn, Robert Marcus, Wolfgang Hiddemann, Marek Trněný, Mikkel Z. Oestergaard, Magdalena Klanova
Purpose:Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b5efac80c8286475bb0868688eb644
https://doi.org/10.1158/1078-0432.c.6528176
https://doi.org/10.1158/1078-0432.c.6528176
Autor:
Günter Fingerle-Rowson, Tina Nielsen, Jeffrey M. Venstrom, Christian Klein, Andres Cardona, Christopher R. Bolen, Nathalie Spielewoy, Deniz Sahin, Andrea Knapp, Harald Zeuner, Valentin Goede, Alexandra Bazeos, Umberto Vitolo, Laurie H. Sehn, Robert Marcus, Wolfgang Hiddemann, Marek Trněný, Mikkel Z. Oestergaard, Magdalena Klanova
Baseline patient and disease characteristics in FL and DLBCL patients with NKCCs available (analysis population) and in the GALLIUM and GOYA ITT populations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ebc5ad55bc74698cc02be8b8ab219f7
https://doi.org/10.1158/1078-0432.22472264
https://doi.org/10.1158/1078-0432.22472264
Autor:
Günter Fingerle-Rowson, Tina Nielsen, Jeffrey M. Venstrom, Christian Klein, Andres Cardona, Christopher R. Bolen, Nathalie Spielewoy, Deniz Sahin, Andrea Knapp, Harald Zeuner, Valentin Goede, Alexandra Bazeos, Umberto Vitolo, Laurie H. Sehn, Robert Marcus, Wolfgang Hiddemann, Marek Trněný, Mikkel Z. Oestergaard, Magdalena Klanova
Association between baseline peripheral blood NKCC and tumor NK cell gene expression in FL (A) and DLBCL (B)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dd681789354e95b95eedb7f0cb0f7c1
https://doi.org/10.1158/1078-0432.22472267.v1
https://doi.org/10.1158/1078-0432.22472267.v1
Autor:
Andrew Lister, Maria Gomes da Silva, John F. Seymour, Harald Zeuner, Jonathan Farhi, John Catalano, Véronique Dorvaux, Sirpa Leppä, David Simpson, Loic Ysebaert, Steven Le Gouill, David Belada, Anne Sonet, Emmanuel Bachy, Pauline Brice, Luc Xerri, Tanin Intragumtornchai, Lars Møller Pedersen, Anne Vekhoff, Sylvie Glaisner, Jane Estell, Gilles Salles, Alejandro Martín, Hervé Tilly, Olivier Casasnovas, François Lemonnier, Fritz Offner, Jean Gabarre, Armando López-Guillermo, Gustavo Milone, Pierre Feugier
Publikováno v:
Journal of Clinical Oncology
PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582 ) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma co
Autor:
Magdalena Klanova, Jeffrey M. Venstrom, Marek Trněný, Mikkel Z. Oestergaard, Christian Klein, Umberto Vitolo, Andrea Knapp, Valentin Goede, Tina Nielsen, Robert Marcus, A. Cardona, Deniz Sahin, Wolfgang Hiddemann, Alexandra Bazeos, Laurie H. Sehn, Christopher R. Bolen, Harald Zeuner, Günter Fingerle-Rowson, Nathalie Spielewoy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(15)
Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with
Autor:
Wolfgang Hiddemann, Robert Marcus, Martin J. S. Dyer, Guillaume Cartron, Georg Hess, Ram Malladi, Michael Herold, Andrea Knapp, Michael Kneba, David Cunningham, Chiara Rusconi, Christian Buske, John G. Gribben, Takayuki Ishikawa, Harald Zeuner, Jeffrey D Neidhart, William Townsend, Ulrich Keller, Jun Zhu, Olivier Catalani
Publikováno v:
Blood. 132:1597-1597
Introduction: Immunochemotherapy is standard of care treatment for previously untreated patients (pts) with advanced stage follicular lymphoma (FL). However, the majority of pts relapse, with around 20% relapsing within 2 years. Obinutuzumab (GA101;
Autor:
Robert MacEwan, Robert Marcus, Sally F. Barrington, Václav Ptáčník, Judith Trotman, Andrew Davies, Michel Meignan, Wolfgang Hiddemann, Harald Zeuner, András Rosta, David Belada, Carolyn Owen, Federico Mattiello, Tina Nielsen, Deniz Sahin
Publikováno v:
Blood. 132:2882-2882
Introduction: Evidence suggests that baseline 18fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography-derived parameters, such as metabolic tumor volume (MTV) and maximum standardized uptake value (SUVmax), may predict progr
Autor:
Alessandra Tedeschi, Kaspar Rufibach, Marek Trněný, Günter Fingerle-Rowson, Ann Janssens, Eva Hoster, Helen McCarthy, András Rosta, Harald Zeuner, P. Schmidt, Michael Herold, Wolfgang Hiddemann, Christopher Pocock, Robert Marcus, A. Burciu
Publikováno v:
Hematological Oncology. 35:146-147
Autor:
Andrea Knapp, Laurie H. Sehn, Marek Trněný, Christopher R. Bolen, Valentin Goede, Tina Nielsen, Denis Sahin, Nathalie Danesi, Jeffrey M. Venstrom, Harald Zeuner, Susan Robson, Günter Fingerle-Rowson, Magdalena Klanova, Wolfgang Hiddemann, Alexandra Bazeos, Robert Marcus, Mikkel Z. Oestergaard, Umberto Vitolo
Publikováno v:
Blood. 130:727-727
Introduction: Natural killer (NK) cells are key elements of the innate immune system. Obinutuzumab (GA101; G) is an anti-CD20 monoclonal antibody with enhanced direct cell death activity and antibody-dependent cellular cytotoxicity (ADCC) vs rituxima
Publikováno v:
Cancer Weekly; 4/30/2024, p622-622, 1p